AR103680A1 - Inhibidores selectivos de bace1 - Google Patents

Inhibidores selectivos de bace1

Info

Publication number
AR103680A1
AR103680A1 ARP160100396A ARP160100396A AR103680A1 AR 103680 A1 AR103680 A1 AR 103680A1 AR P160100396 A ARP160100396 A AR P160100396A AR P160100396 A ARP160100396 A AR P160100396A AR 103680 A1 AR103680 A1 AR 103680A1
Authority
AR
Argentina
Prior art keywords
bace1
selective inhibitors
compound
pharmaceutical use
salt acceptable
Prior art date
Application number
ARP160100396A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR103680A1 publication Critical patent/AR103680A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Abstract

La presente solicitud proporciona un compuesto o una sal aceptable para uso farmacéutico en el tratamiento del Alzheimer. Reivindicación 1: Un compuesto de la fórmula (1) en donde R es metilo, etilo, o ciclopropilo; o una sal aceptable para uso farmacéutico.
ARP160100396A 2015-02-23 2016-02-12 Inhibidores selectivos de bace1 AR103680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562119391P 2015-02-23 2015-02-23

Publications (1)

Publication Number Publication Date
AR103680A1 true AR103680A1 (es) 2017-05-24

Family

ID=55442893

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100396A AR103680A1 (es) 2015-02-23 2016-02-12 Inhibidores selectivos de bace1

Country Status (27)

Country Link
US (1) US9522923B2 (es)
EP (1) EP3262051B1 (es)
JP (1) JP6111001B1 (es)
KR (1) KR101945139B1 (es)
CN (1) CN107257801B (es)
AR (1) AR103680A1 (es)
AU (1) AU2016223072B2 (es)
BR (1) BR112017013936A2 (es)
CA (1) CA2972098A1 (es)
CL (1) CL2017002090A1 (es)
CO (1) CO2017008382A2 (es)
CR (1) CR20170315A (es)
DO (1) DOP2017000178A (es)
EA (1) EA031546B1 (es)
EC (1) ECSP17054980A (es)
GT (1) GT201700185A (es)
IL (1) IL252969A0 (es)
MX (1) MX367940B (es)
NZ (1) NZ732940A (es)
PE (1) PE20171337A1 (es)
PH (1) PH12017501523A1 (es)
SG (1) SG11201705764SA (es)
SI (1) SI3262051T1 (es)
TN (1) TN2017000355A1 (es)
TW (1) TWI627177B (es)
WO (1) WO2016137788A1 (es)
ZA (1) ZA201704293B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CA2977667C (en) 2015-03-19 2019-08-20 Eli Lilly And Company Aminothiazine compounds useful as selective bace1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017167952A1 (en) 2016-04-01 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JP2019530647A (ja) * 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Bace−1阻害剤と抗n3pglu aベータ抗体の併用療法
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3630724B1 (en) 2017-05-22 2021-04-28 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112019024195A2 (pt) 2017-05-22 2020-06-23 Janssen Pharmaceuticals, Inc. Composto e composição farmacêutica de derivados de indolina substituídos como inibidores da replicação viral da dengue

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201004961A (en) 2005-06-14 2010-02-01 Schering Corp Aspartyl protease inhibitors
PE20091438A1 (es) 2008-01-18 2009-09-26 Eisai Randd Man Co Ltd Derivados fusionados de aminodihidrotiazina
CA2727859C (en) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
CA2738150A1 (en) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
JP5554346B2 (ja) 2009-12-09 2014-07-23 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
EP2511269A4 (en) 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI639607B (zh) * 2013-06-18 2018-11-01 美國禮來大藥廠 Bace抑制劑
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Also Published As

Publication number Publication date
CL2017002090A1 (es) 2018-04-13
CO2017008382A2 (es) 2017-11-30
AU2016223072A1 (en) 2017-07-13
WO2016137788A1 (en) 2016-09-01
TWI627177B (zh) 2018-06-21
US20160244465A1 (en) 2016-08-25
JP2017511806A (ja) 2017-04-27
EP3262051A1 (en) 2018-01-03
KR101945139B1 (ko) 2019-02-01
ECSP17054980A (es) 2017-11-30
BR112017013936A2 (pt) 2018-01-02
CR20170315A (es) 2017-08-14
US9522923B2 (en) 2016-12-20
IL252969A0 (en) 2017-08-31
SG11201705764SA (en) 2017-08-30
NZ732940A (en) 2019-06-28
EP3262051B1 (en) 2019-10-02
EA031546B1 (ru) 2019-01-31
MX2017010861A (es) 2017-12-11
MX367940B (es) 2019-09-12
CN107257801A (zh) 2017-10-17
CA2972098A1 (en) 2016-09-01
GT201700185A (es) 2018-11-23
TW201643170A (zh) 2016-12-16
PH12017501523A1 (en) 2018-02-05
SI3262051T1 (sl) 2019-11-29
CN107257801B (zh) 2019-08-13
TN2017000355A1 (en) 2019-01-16
JP6111001B1 (ja) 2017-04-05
DOP2017000178A (es) 2017-09-15
KR20170103971A (ko) 2017-09-13
AU2016223072B2 (en) 2018-11-15
ZA201704293B (en) 2019-01-30
EA201791684A1 (ru) 2017-12-29
PE20171337A1 (es) 2017-09-13

Similar Documents

Publication Publication Date Title
AR103680A1 (es) Inhibidores selectivos de bace1
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
TW201613872A (en) IRAK4 inhibiting agents
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
EA201791576A1 (ru) Ингибитор jak
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201791304A1 (ru) Производные изохинолина для лечения вич
SV2016005351A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
NI201800071A (es) Compuestos de isoindol
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
BR112017000730B8 (pt) Derivados de pirrolidinona como inibidores de metap-2, e medicamentos
SV2016005313A (es) Derivados de carboxamida
UY36123A (es) Derivados de carboxamida
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция

Legal Events

Date Code Title Description
FB Suspension of granting procedure